Eric Goffin

Eric Goffin

Auto-generated profile, based on publicly available information

Eric Goffin

Center for Interdisciplinary Research on Medicines—Laboratory of Medicinal Chemistry, University of Liège, Liège, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
NENajla El-Hachem
Najla El-Hachem
MLMarine Leclercq
Marine Leclercq
MRMiguel Susaeta Ruiz
Miguel Susaeta Ruiz
RVRaphael Vanleyssem
Raphael Vanleyssem
KSKateryna Shostak
Kateryna Shostak
PCPierre Close
Pierre Close
Transfer RNA dynamics contribute to cancer development through regulation of codon-specific messenger RNA translation. Specific aminoacyl-tRNA synthetases can either promote or suppress tumourigenesis. Here we show that valine aminoacyl-tRNA synthetase (VARS) is a key player in the codon-biased translation reprogramming induced by resistance to targeted (MAPK) therapy in melanoma. The proteome rewiring in patient-derived MAPK therapy-resistant melanoma is biased towards the usage of valine and coincides with the upregulation of valine cognate tRNAs and of VARS expression and activity. Strikingly, VARS knockdown re-sensitizes MAPK-therapy-resistant patient-derived melanoma in vitro and in vivo. Mechanistically, VARS regulates the messenger RNA translation of valine-enriched transcripts, among which hydroxyacyl-CoA dehydrogenase mRNA encodes for a key enzyme in fatty acid oxidation. Resistant melanoma cultures rely on fatty acid oxidation and hydroxyacyl-CoA dehydrogenase for their survival upon MAPK treatment. Together, our data demonstrate that VARS may represent an attractive therapeutic target for the treatment of therapy-resistant melanoma.


1 December 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EGEric Goffin
Eric Goffin
NJNicolas Jacques
Nicolas Jacques
LMLucia Musumeci
Lucia Musumeci
ANAlain Nchimi
Alain Nchimi
COCécile Oury
Cécile Oury
BPBernard Pirotte
Bernard Pirotte

5 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
PFPierre Francotte
Pierre Francotte
YBYasmin Bay
Yasmin Bay
EGEric Goffin
Eric Goffin
TCThomas Colson
Thomas Colson
CLCindy Lesenfants
Cindy Lesenfants
BPBernard Pirotte
Bernard Pirotte
The synthesis and biological evaluation on AMPA and kainate receptors of new examples of 3,4-dihydro-2 H -1,2,4-thieno[3,2- e ]-1,2,4-thiadiazine 1,1-dioxides is described. The introduction of a cyclopropyl chain instead of an ethyl chain at the 4-position of the thiadiazine ring was found to dramatically improve the potentiator activity on AMPA receptors, with compound 32 (BPAM395) expressing in vitro activity on AMPARs (EC2x = 0.24 µM) close to that of the reference 4-cyclopropyl-substituted benzothiadiazine dioxide 10 (BPAM344). Interestingly, the 4-allyl-substituted thienothiadiazine dioxide 27 (BPAM307) emerged as the most promising compound on kainate receptors being a more effective potentiator than the 4-cyclopropyl-substituted thienothiadiazine dioxide 32 and supporting the view that the 4-allyl substitution of the thiadiazine ring could be more favorable than the 4-cyclopropyl substitution to induce marked activity on kainate receptors versus AMPA receptors. The thieno-analogue 36 (BPAM279) of the clinically tested S18986 ( 11 ) was selected for in vivo evaluation in mice as a cognitive enhancer due to a safer profile than 32 after massive per os drug administration. Compound 36 was found to increase the cognition performance in mice at low doses (1 mg/kg) per os suggesting that the compound was well absorbed after oral administration and able to reach the central nervous system. Finally, compound 32 was selected for co-crystallization with the GluA2-LBD (L504Y,N775S) and glutamate to examine the binding mode of thienothiadiazine dioxides within the allosteric binding site of the AMPA receptor. At the allosteric site, this compound established similar interactions as the previously reported BTD-type AMPA receptor modulators. Highlights: The study explored AMPA/kainate receptor PAMs belonging to thienothiadiazine dioxides The 4-cyclopropyl-substituted compound 32 was the most potent AMPA receptor modulator 4-Allyl substitution improved activity and selectivity for kainate receptors The tricyclic compound 36 expressed cognitive improvement in vivo in mice Compound 32 was co-crystallized with GluA2-LBD to examine receptor binding mode Graphical

19 December 2024 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
MSMichael Schnekenburger
Michael Schnekenburger
EGEric Goffin
Eric Goffin
MSMatthieu Schoumacher
Matthieu Schoumacher
NTNikolay Tumanov
Nikolay Tumanov
AMAnge Mouithys-Mickalad
Ange Mouithys-Mickalad
BPBernard Pirotte
Bernard Pirotte